Black Diamond Therapeutics (BDTX) Income from Continuing Operations: 2018-2021
Historic Income from Continuing Operations for Black Diamond Therapeutics (BDTX) over the last 4 years, with Dec 2021 value amounting to -$123.4 million.
- Black Diamond Therapeutics' Income from Continuing Operations fell 16.25% to -$25.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$111.6 million, marking a year-over-year decrease of 68.00%. This contributed to the annual value of -$123.4 million for FY2021, which is 88.32% down from last year.
- Latest data reveals that Black Diamond Therapeutics reported Income from Continuing Operations of -$123.4 million as of FY2021, which was down 88.32% from -$65.5 million recorded in FY2020.
- In the past 5 years, Black Diamond Therapeutics' Income from Continuing Operations ranged from a high of -$8.9 million in FY2018 and a low of -$123.4 million during FY2021.
- Its 3-year average for Income from Continuing Operations is -$72.6 million, with a median of -$65.5 million in 2020.
- Data for Black Diamond Therapeutics' Income from Continuing Operations shows a maximum YoY slumped of 224.39% (in 2019) over the last 5 years.
- Yearly analysis of 4 years shows Black Diamond Therapeutics' Income from Continuing Operations stood at -$8.9 million in 2018, then tumbled by 224.39% to -$28.9 million in 2019, then slumped by 126.98% to -$65.5 million in 2020, then crashed by 88.32% to -$123.4 million in 2021.